UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or ...

Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results • Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), which highlight a growing number of potential clinical program catalysts • Our first neuroscience phenomap was opt ...

In an environment where the typical small biotech name is riskier than not, this one is curiously different.As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the right biotechnology name though...ka-ching! Holding a big enough stake in one of these winners could make you a millionaire.With that as the backdrop, here's a closer look at a curious biotech name, Recu ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.40, demonstrating a +1.27% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.41%. Meanwhile, the Dow gained 0.69%, and the Nasdaq, a tech-heavy index, added 0.8%.Shares of the biotechnology company have appreciated by 4.29% over the course of the past month, outperforming the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97%.Investors will be eagerly watching for the performance ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.68, demonstrating a -0.89% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.33%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, lost 0.56%. The biotechnology company's shares have seen an increase of 9.24% over the last month, surpassing the Medical sector's loss of 4.31% and the S&P 500's gain of 1.83%. Investors will be eagerly watching for the performa ...

This company stands to benefit from a shifting pharmaceutical industry landscape. As a biotech that's leaning heavily on artificial intelligence (AI) in every aspect of its business, Recursion Pharmaceuticals (RXRX 1.89%) is hooked into a handful of big trends that will likely define the future of its industry. There isn't any guarantee that the company will be a good investment on the force or direction of those trends alone. But there are three which are especially bullish for the stock thanks to how it's ...

Recursion Pharmaceuticals (RXRX) closed at $6.36 in the latest trading session, marking a +0.47% move from the prior day. This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%.The investment community will be closely monitoring the performance of Recursion Ph ...

Wood has a stake in this stock, but it's hardly an "all-in" bet. Artificial intelligence (AI) is changing the way we do business. Companies are racing to implement it in umpteen different ways, knowing that the most successful will reap immense financial benefits. That's why investors are also searching for the most exciting AI stocks, but picking the right one might not be easy. How about getting some inspiration from famous investors? Cathie Wood, the CEO of Ark Invest, has several AI stocks in her invest ...

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. The artificial intelligence (AI) revolution is pushing up the overall stock market, but not every AI stock is performing well. Shares of Recursion Pharmaceuticals (RXRX 1.51%) are down by more than half from a peak they set this spring. The start-up drugmaker disappointed investors with lackluster results for its lead candidate in September. Luckily, it has a deep pipeline of less-adva ...

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. Artificial intelligence (AI) is poised to revolutionize the global economy. By 2030, AI could add $15.7 trillion to worldwide GDP, a 26% increase, according to a report by PwC, a leading global consulting firm. This projected growth is expected to stem from significant productivity gains and increased consumer demand. A study by the World Economic Forum, an international organization ...